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Abbreviations 
 
ACS Acute coronary syndrome 
ALB Albumin 
ALT Alanine aminotransferase 
ANP Atrial natriuretic peptide 
AST Aspartate aminotransferase 
BMI Body mass index 
BNP B-type natriuretic peptide 
BPM Beats per minute 
BUN Blood urea nitrogen 
CKD Chronic kidney disease 
CLSI Clinical and Laboratory Standards Institute 
CNP C-type natriuretic peptide 
CNS Central nernous system 
CRE Creatinine 
cTn Cardiac troponin 
cTnI Cardiac troponin I 
cTnT Cardiac troponin T 
CTR Cardiothoracic ratio 
CV Coefficient of variation 
CysC Cystatin C 
DBP Diastolic blood pressure 
eGFR Estimated glomerular filtration rate 
ET-1 Endothelin-1 
FBG Fasting blood glucose 
FRS Framingham risk score 
GDF-15 Growth-differentiation factor 15 
GGT Gamma glutamyl transferase 
HbA1c Hemoglobin A1c 
HDL-C High-density lipoprotein cholesterol 
HE4 Human epididymis protein 4 
hFABP Heart-type fatty acid-binding protein 
HFmrEF Heart failure with mid-range ejection fraction 
HFpEF Heart failure with preserved ejection fraction 
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HFrEF Heart failure with reduced ejection fraction 
HR Heart rate 
Ht Hematocrit 
ICAM Intracellular adhesion molecule 
IHD Ischemic heart disease 
LDL-C Low-density lipoprotein cholesterol 
LoB Limit of blank 
LoD Limit of detection 
LoQ Limit of quantitation 
LVEF Left ventricular ejection fraction 
MR-proADM Mid-regional pro-adrenomedullin 
NGAL Neutrophil gelatinase-associated lipocalin 
NPPB Natriuretic peptide precursor B 
NRG-1 Neuregulin 1 
NT-proBNP N-terminal pro B-type natriuretic peptide 
PLT Platelet count 
RAAS Renin-angiotensin-aldosterone system 
RBC Red blood cell count 
SBP Systolic blood pressure 
SD Standard deviation 
SEM Structural equation modeling 
sST2 Soluble suppression of tumorigenicity 2 
TG Trilyceride 
UA Uric acid 
ULN Upper limit of normal 
VC Vital capacity 
WBC White blood cell count 
WC Waist circumference 
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Chapter 1. Background of This Study 
 
1. Cardiovascular Disease in an Aging Country Like Japan 
Cardiovascular disease is the second highest cause of death in Japan and the 
incidence is increasing year by year. Ratio of population over 65 of age has 
exceeded 27% of the total population as of 2016 which is at the top in the world and 
is expected to approach 40% in 50 years [1]. The national medical expenditure in 
Japan which already exceeds 40 trillion yen is speculated to exceed 50 trillion yen in 
2030 [2]. It may well be construed, therefore, as that Japan is the front runner 
among aging countries in the world so that Japan is expected to show to the 
following countries solutions or directions for economically and culturally 
sustainable development. One of the solutions would be to find diseases at their 
early stage and intervene with them before they develop into severe status so that 
people could live healthy life longer with the less medical expenditure.  
According to statistics, more than 70% of the cause of the sudden death is 
attributed to cardiac diseases by which 30,000 to 40,000 people die every year in 
Japan [3]. The number of patients with heart failure in Japan is estimated to be 
approximately one million currently, which is 0.8% of the total population and the 
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number is estimated to reach 1.3 million by 2030 [4]. It is pointed out that the 
patients with heart failure, in many cases, are diagnosed as having heart failure only 
after their disease status have been advanced [5]. Under this situation, I believe, to 
develop an efficient method to screen the general population for potential 
cardiovascular diseases, such as a blood test for detection of biomarkers, would be 
extremely important for the welfare of the aging society like Japan.  
 
2. Overview of Groups of Cardiovascular Diseases 
In terms of the number of deaths by cardiovascular disease groups, heart failure is at 
the top (37%) among cardiovascular disease groups followed by myocardial 
infarction (18%), other ischemic cardiovascular diseases (17%), and arrhythmia 
(16%) as shown in Fig. 1 [6]. Followings are brief descriptions on the above 
cardiovascular disease groups. 
 
1) Heart Failure 
Heart failure is a general term to define cardiovascular diseases that show 
reduced heart function by increased myocardial mass and left ventricular 
hypertrophy as a consequence of long-term exposure to elevated mechanical 
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stress by hypertension or some other factors. This disease group is categorized 
further into three sub-groups according to the function of left ventricle ejection 
fraction (LVEF); heart failure with preserved ejection fraction (HFpEF), heart 
failure with mid-range ejection fraction (HFmrEF) and heart failure with 
reduced ejection fraction (HFrEF). The LVEF’s of HFpEF, HFmrEF and HFrEF 
are defined as equal to or more than 50%, equal to or more than 40% and less 
than 50%, less than 40%, respectively [7]. 
 
2) Ischemic Heart Disease 
Ischemic cardiovascular disease is a general term to define cardiovascular 
diseases caused by disrupted blood stream at coronary arteries such as by plaque 
rupture, embolism or dissection. Myocardial infarction belongs to this group 
which is defined as a cardiovascular disease with blocked blood stream at 
coronary arteries by plaque rupture and the thrombosis [8].  
 
3) Arrhythmia 
Arrhythmia is a general term to define cardiovascular diseases with irregular 
heart beat which include tachycardia (>100 beats per minute, or bpm), 
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bradycardia (<60 bpm) and a one with aberrant pulses [9]. 
 
4) Other Cardiovascular Diseases [10, 11] 
Other than the cardiovascular diseases described above, there are pericardial 
heart disease, valvular heart disease, cardiomyopathies, congenital 
cardiovascular diseases, etc.  
Pericardial cardiovascular disease is a general term to define diseases with 
defective pericardium, which includes acute pericarditis, pericardial effusion, 
cardiac tamponade, and constrictive pericarditis. 
Valvular heart disease is a general term to define cardiovascular diseases 
caused by the disorder at heart valves such as pulmonary valve, aortic valve, 
mitral valve, or tricuspid valve.  
Cardiomyopathy is a general term to define cardiovascular diseases with 
disorder at the heart muscle. Although primary cardiomyopathies are generally 
confined to the disorder at the heart muscle, secondary cardiomyopathies not 
only show disorders at myocardium but also at systemic multi-organs. 
Congenital cardiovascular disease is a general term to define cardiovascular 
diseases caused by inherited genetic and structural defects. There are six major 
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categories in the congenital heart defects; arterial septal defects, congenitally 
corrected transposition of the great vessels, tetraology of Fallot, transposition of 
the great arteritis, Ebstein anomaly and Fontan circulation. 
 
3. Risk Factors for Cardiovascular Diseases 
Since 1960’s, studies from Framingham and other epidemiological cohorts 
contributed in establishing a concept of ‘risk factors’ for the development of 
cardiovascular diseases, which include hypertension, dyslipidemia, diabetes 
mellitus and smoking habit [12]. Basing on this concept, many researchers 
attempted to create multivariable algorithms for risk scores of cardiovascular 
diseases by applying the data obtained in the Framingham Heart Study. Among 
these efforts, D’Agostino et al. proposed a multivariable risk assessment tool that 
enables physicians to identify high-risk population using measurements readily 
available at clinics (e.g. sex, age, high-density lipoprotein cholesterol (HDL-C), 
systolic blood pressure (SBP), smoking habit, diabetes, etc.), where the risk score 
derived from this algorithm is defined as the probability of 10-year cardiovascular 
incidence [13]. 
In Chapter 2, I assessed the associations between selected biomarkers and risk 
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factors mentioned above as well as the association with the Framingham Risk Score 
(FRS) calculated by the D’Agostino’s algorithm. 
 
4. Selection of Suitable Biomarkers for the Screening of 
Cardiovascular Diseases [14] 
 
1) Biomarkers’ Contribution in Preventing the Development of 
Cardiovascular Diseases 
As described in the previous section, risk factors such as hypertension, 
dyslipidemia, diabetes mellitus, chronic kidney disease or smoking habit have 
been proven to have strong association with the development of cardiovascular 
diseases (Fig. 2). Because it usually takes many years for people having these 
risk factors to develop serious cardiovascular diseases, it is difficult to decide at 
which time point doctors need to intervene (e.g. to do operational treatment) in 
addition to instructing the patients to improve their lifestyle (e.g. to go on a diet, 
to do more exercise, etc.). In this sense, desirable cardiac biomarkers would be 
those which show direct sign that the heart is starting to go wrong so that the 
doctors would be able to know when to intervene. 
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2) Overview of Candidate Biomarkers Related with Cardiovascular 
Diseases 
To overview established and emerging biomarkers that are related with 
cardiovascular diseases, I listed up representing eleven biomarkers in Table 1 
and Fig. 3. More specifically, I summarized the physico-chemical property of the 
molecule (e.g. protein, peptide, lectin, etc.), the function (e.g. hormone, enzyme, 
structural protein, receptor, etc.), and the suggested indication for its clinical 
usage in Table 1 while I categorized these biomarkers in the context of 
physiological responses such as myocardial injury, myocardial stress, oxidative 
stress, inflammation and so on in Fig. 3. As can be seen, some biomarkers 
appear in multiple categories owing to the nature of the biomarkers (e.g. sST2, 
Pentraxin 3).  
 
3) Specifications of Desirable Biomarkers from Analytical Aspect 
From the aspect of analytical requirements, desirable biomarkers are expected to 
have good performances in sensitivity, specificity, reproducibility, accessibility, 
cost-effectiveness. From the analytical aspect, sensitivity is defined as the 
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minimal concentration that the assay can detect (for the detail, see “Three 
Definitions of Sensitivity; LoB, LoD and LoQ” in Section 6 in this chapter), 
specificity is defined as the ability of the assay to discern the target molecule 
from others, reproducibility is defined as the ability of the assay to quantitate 
within pre-defined fluctuation range, accessibility means how easily the assay 
can be accessed including the factors of reagent supply and automation, 
cost-effectiveness means how effectively the assay cost can be managed in 
clinical laboratories (e.g. less labor intensive work).  
 
4) Specifications of Desirable Biomarkers from Clinical Aspect 
From the aspect of clinical requirements, desirable biomarkers are expected to 
have good specificity to the disease of interest and show good performances in 
the diagnosis, assessment of severity, monitoring of the treatment and 
assessment of prognosis. Specificity in terms of clinical aspect means specific 
association of the target molecule with the target disease. Therefore, if a target 
molecule is not only released from heart muscle but also from skeletal muscle, 
for example, the specificity of this biomarker could be considered as 
“compromised” in terms of the specificity for heart disease.  
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5) Selection of Biomarkers for the Screening of Cardiovascular 
Diseases 
Because there are variations in analytical performances by assays from 
different manufacturers, I focused on the clinical characteristics of the target 
biomarker for the selection here. As shown in Table 2, I assessed 13 biomarkers 
from the clinical aspects of specificity, utilities for diagnosis, severity, 
monitoring and prognosis as mentioned above. For the assessment, I used three 
categories; satisfactory (○), not decided or compromised (△), and not suitable 
(× ) and categorized each by previously reported evidences (Table 2). 
Specification was categorized as “satisfactory” when it is released only from the 
target organ and not affected by other diseases. For example, the specificity of 
cardiac troponin T (cTnT) was categorized as “not decided or compromised” 
because it is released not only from the heart but also from the skeletal muscle in 
patients with renal failure [15] or skeletal muscle disease [16]. Similarly,  
NT-proBNP was categorized as “not decided or compromised” because its level 
is significantly affected by renal failure [17]. 
As the result of the assessment, B-type natriuretic peptide (BNP) and cardiac 
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troponin I (cTnI) showed the best clinical performances among the 13 
biomarkers as shown in Table 2. Because BNP is released by hemodynamic 
stress on the heart especially when the heart wall is thickened, or at the state of 
hypertrophy, while cTnI is released by myocardial injuries such as when there is 
necrosis on the myocardium, I thought these two biomarkers would cover 
broader sub-population at risks with clinical and sub-clinical cardiovascular 
diseases in the general population as illustrated in Fig. 4. I, therefore, assumed 
that the combination assay of BNP and cTnI would be a better screening method 
to cover broader sub-population than single assays and decided to investigate the 
validity of the combination assay in this study.  
 
5. Objectives of This Study 
Because of the reasons illustrated above, I selected the two biomarkers, BNP and 
cTnI, and assessed the validity of the combination assay of the two biomarkers in 
the general population. More specifically, the objectives of this study are as follows;  
1) To assess whether BNP or cTnI shows association with the risk factors for 
cardiovascular diseases as mentioned earlier,  
2) To assess whether BNP and cTnI detect different populations and different types 
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of (sub-clinical) cardiovascular diseases, and 
3) To assess whether there is any positive or inverted association between BNP and 
cTnI. 
 
6. Statistical Analyses 
 
1) Shapiro-Wilk Test 
Shapiro-Wilk test is one of the most popular statistical methods to assess 
whether a distribution of a given numerical group conforms with Gaussian 
distribution or not [18]. Gaussian distribution is called “parametric,” whereas 
non-Gaussian distribution is called “non-parametric”. 
 
2) Student’s T-test [19, 20] 
Student’s t-test is a statistical method to assess whether the difference between 
two parametric distributions is significant. When you compare two populations 
where samples of the two populations can be paired (e.g. weights before and 
after exercise of the same person), “paired t-test” is used, while you compare 
two populations with unpaired samples, “unpaired t-test” is used. 
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3) Wilcoxon’s Test [21] 
Wilcoxon’s test is a statistical method to assess whether the difference between 
two non-parametric distributions is significant. 
 
4) Linear Regression Analyses [22] 
Linear regression analysis is a statistical method to assess whether a given 
variable is significantly associated with a variable of interest. For example, 
association of age (shown in the X-axis) against cTnI (shown in the Y-axis) is 
analyzed by examining the linear relationship between the two variables as 
illustrated in Fig. 5. “Univariable linear regression” analyzes the linear 
relationship between the two variables as mentioned above by the equation  
Y = a × X + b 
where “a” is the slope and “b” is the y-intersect of the line. On the other hand, 
“multivariable regression” analyzes the linear relationship between a variable of 
interest (designated as Y) and multiple independent variables (designated as Xi) 
by the following equation 
Y = a1 × X1 + a2 × X2+…+ an × Xn + b. 
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This model permits the computation of a regression coefficient ai for each 
independent variable Xi. 
 
5) Exclusion of Outlying Test Results by Dixon’s Method [23] 
Dixon’s method is a statistical method to assess whether outlying data should be 
excluded from further statistical analyses. The formula is defined as D/R, where 
D is a difference between the largest (or smallest) value and the second largest 
(or smallest) value, and R is the range of all the data. Reed et al. suggests that 
one-third as a practical cut-off.  
 
6) Three Definitions of Sensitivity; LoB, LoD and LoQ [24, 25] 
As there are several ways to define sensitivity, limit of blank (LoB), limit of 
detection (LoD) and limit of quantitation (LoQ) are standard methods to define 
the sensitivity proposed by Clinical and Laboratory Standards Institute (CLSI) 
as illustrated in the guideline EP17-A, “Protocols for Determination of Limits of 
Detection and Limits of Quantitation”.  
LoB is obtained by measuring replicates of a blank sample and is calculated 
from the following formula with the mean and the standard deviation (SD);  
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LoB = mean blank + 1.645 x (SD blank) [Fig. 6] 
where SD blank signifies a standard deviation of the blank sample, 
LoD is estimated by the following formula;  
LoD = LoB + 1.645 x (SD low concentration sample) [Fig. 6] 
where SD low concentration sample signifies a standard deviation of the low 
concentration sample and 1.645 signifies one-sided 95% confidence interval. 
LoQ is defined as the lowest concentration at which the sum of functional 
sensitivity and bias is within certain predefined allowance range where the 
functional sensitivity is defined as the lowest concentration that shows CV% 
within predefined allowance range, and the bias is defined as the percentage of 
deviation from the linearity. For the assessment of LoQ in the clinical practice, 
30% is one of the frequently used allowance ranges [Fig. 7].  
 
7) Covariance Structure Analysis [26] 
Covariance Structure Analysis, or Structural Equation Modeling, is a general 
statistical modeling technique which could be understood as a combination of 
factor analysis and multiple regression analysis. The covariance structure is a 
structure where the relationships between the variables are connected by path 
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coefficients between them (Fig. 8). By constructing the covariance structure 
model, or path model, you would be able to assess the strength and the direction 
(positive or inversed) of the relationships between the variables. 
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Table 1: Summary of Cardiac Biomarkers 
 
 Pathophysiology and Proposed Clinical Utility 
Copeptin Copeptin is a C-terminus portion of pro-vasopressin, which is synthesized and 
secreted from the hypothalamus in response to change in plasma osmolarity and 
reduced cardiac output. In patients with heart failure, copeptin levels are highly 
predictive of mortality independent of other risk factors.  
Cystatin C Cystatin C (CysC) is a cysteine protease inhibitor produced at a constant rate by 
all nucleated cells of the body. Because several properties of CysC make it 
superior to creatinine as a measure of glomerular filtration rate (GFR), CysC is 
expected to be used as a marker for both acute kidney injury and chronic renal 
failure.  
Endothelin 1 Endothelin-1 (ET-1) is a profibrotic hormone primarily secreted by endothelial 
cells, cardiomyocytes, smooth muscle cells and macrophages. Increased levels of 
ET-a have been noted in patients with chronic heart failure, but the prognostic 
value is not clear. 
Galectin-3 Galectin-3 is a member of a family of soluble  -galactoside-binding lectins. 
Galectin-3 was initially identified as a mediator of tumor growth, but new data 
indicates a potential link between inflammation and fibrosis. In chronic heart 
failure, Galectin-3 promotes maladaptive cardiac remodeling by augmenting 
fibrosis and modulating immune response. 
GDF-15 Growth-differentiation factor 15 (GDF-15) is a member of the transforming 
growth factor- cytokine superfamily expressed in myocytes, smooth muscle 
cells, endothelial cells, adipocytes and atherosclerotic plaques. Studies have 
shown that elevated levels of GDF-15 are strongly associated with poor 
prognosis in patients with coronary diseases. 
cTn Cardiac troponin I (cTnI) and cardiac troponin T (cTnT) are structural proteins 
expressed in myocardium. High sensitive assays are now able to detect not only 
ischemic necrosis of myocardium but also micro necrosis due to causes other 
than ischemia. cTn is currently used primarily for the diagnosis of acute coronary 
syndrome, but also is expected to be used as a prognostic marker as well. 
MR-proADM Mid-regional pro-adrenomedullin (MR-rpoADM) is a stable prohormone of 
adrenomedullin, which is a hormone having potent vasodilatory and natriuretic 
effects. Elevated levels of MR-proADM is strongly associated with poor 
prognosis of heart failure, but response to medical therapy is inconsistent among 
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several studies. 
Neuregulin 1 Neuregulin 1 (NRG-1) belongs to a family of growth factors that functions via 
receptor tyrosine kinases and has indispensable role in cardiac development and 
functioning. Levels of NRG-1 are independently associated with the severity of 
heart failure, but further studies are needed to establish its value as a prognostic 
marker. 
NGAL Neutrophil gelatinase-associated lipocalin (NGAL) is a small glycoprotein 
released from several types of cell, including epithelial cells, renal tubular cells, 
and hepatocytes, during inflammation or after injury. Measurement of urine 
NGAL is thought to have at least two potential uses; a marker to detect acute 
kidney injury and a predictor of adverse outcomes in chronic heart failure.  
sST2 sST2 is a truncated soluble form of a member of interleukin-1 receptor family. 
Increased levels of sSTs could augment adverse remodeling and deemed to have 
an important prognostic value in patients with acute coronary disease or heart 
failure. 
BNP B-type natriuretic peptide (BNP) is a peptide primarily secreted from ventricular 
myocytes in response to hemodynamic stress. This peptide is extremely useful in 
determining whether heart failure is the cause of acute dyspnea, and in 
determining the severity and prognosis of heart failure. 
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Table 2: Specifications of Cardiac Biomarkers from Clinical Aspect 
 
 Specificity Diagnosis Severity Monitoring Prognosis 
Copeptin × △ ○ △ ○ 
Cystatin C × × ○ △ ○ 
Endothelin 1 × △ △ △ △ 
Galectin-3 × △ ○ × △ 
GDF-15 × △ ○ △ ○ 
cTnI ○ ○ ○ ○ ○ 
cTnT △ ○ ○ ○ ○ 
MR-proADM × △ ○ △ ○ 
Neuregulin 1 △ △ △ △ △ 
NGAL △ ○ ○ ○ △ 
sST2 × × ○ △ ○ 
BNP ○ ○ ○ ○ ○ 
NT-proBNP △ ○ ○ ○ ○ 
○: Satisfactory, △: Not Decided or Compromised, ×: Not Suitable 
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Fig. 1: Percentages of Cardiovascular Deaths by Cardiovascular 
Disease Groups 
Percentages of deaths by the cardiovascular disease groups among the total number of 
deaths by cardiovascular diseases in 2015 in Japan [6]. The cardiovascular disease 
groups include heart failure, myocardial infarction, the other ischemic heart disease, 
arrhythmia and the other cardiovascular diseases.  
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Fig. 2: Significance of Preventive Medicine by Early Detection 
Schematic diagram showing the importance of preventive medicine by early detection. 
Without the early detection and the proper treatment of a sub-clinical cardiovascular 
disease, it could develop into severe and sometimes fatal diseases such as myocardial 
infarction or congestive heart failure. 
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Fig. 3: Biomarkers Related with Cardiovascular Diseases 
Schematic diagram of potential biomarkers related with heart diseases group 
categorized by physiological responses or systems; myocardial injury, oxidative stress, 
inflammation, neurohormones, matrix and remodeling, myocardial stress, vascular 
system, and cardio-renal syndrome.  
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Fig. 4: Detection of Early Signs of Onset by BNP and cTnI 
Schematic diagram to show the expected timing of the biomarker elevation. Following 
the long-term insult by the risk factors such as dyslipidemia, smoking, hypertension, 
diabetes, or chronic kidney disease, myocardium of the heart could be swollen 
(hypertrophy) or injured when BNP or cTnI is released into the blood. 
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Fig.5: Example of Linear Regression 
Example of linear regression illustrated by the correlation between age (X-axis) and 
cTnI (Y-axis). The regression line obtained by the linear regression is shown in red. The 
formula of the regression line and the correlation coefficient are shown at upper right. 
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Fig. 6: LoB (Limit of Blank) and LoD (Limit of Detection) 
Schematic diagrams to show how LoB (limit of blank) and LoD (limit of detection) are 
determined. LoB is determined by adding 1.645SDblank to blank (upper diagram) while 
LoD is determined by identifying the mean of low concentration samples where mean – 
1.645SDlow concentration sample equals the LoB (lower diagram). SDblank: standard deviation 
of the blank. SDlow concentration sample: standard deviation of a given low concentration 
sample. 
Blank
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LoB
LoD
1.645SD
LoB (Limit of Blank)
= Blank + 1.645SDblank
LoD (Limit of Detection)
=Mean where (mean − 1.645SDlow 
concentration sample) equals LoB
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Fig. 7: LoQ (Limit of Quantitation) 
Schematic diagram to show how LoQ (limit of quantitation) is determined. For each 
dilution series sample, sum of CV% and absolute bias% (green) is obtained from CV% 
(blue) and absolute bias% (red). LoQ is determined by identifying the lowest 
concentration that shows the sum of CV% and bias% within predefined allowance range 
(e.g. 30%).  
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Fig. 8: Covariance Structure Analysis 
Schematic diagrams to show how associations between factors (factors X and Y) are 
analyzed by covariance structure analyses. Case1: the simplest case where association 
between two factors is analyzed. Case 2: a case where another factor (factor X2) is 
added to Case 1. Case 3: a generalized case where multiple factors (factors X1 through 
Xn) are analyzed against a factor of interest (factor Y). 
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Chapter 2.  Screening of Cardiovascular Diseases in the 
General Population with B-type Natriuretic Peptide 
and cardiac troponin I 
 
1. Introduction 
In Chapter 1, I selected BNP and cTnI as the two best biomarkers among the 13 
candidate biomarkers for the screening of cardiovascular diseases basing on their 
desirable specificity and sensitivity in the diagnosis, assessment of the disease 
severity, monitoring of treatment efficacy and prediction of the future incidences. 
BNP, a peptide that was discovered by Sudoh et al.[27], is predominantly 
expressed in ventricles and secreted in response to several factors, including 
myocardial stretching, increased myocardial pressure, and cell hypoxia, to bring 
about pharmacological effects, such as vasorelaxation, diuresis, natriuresis, and the 
inhibition of the renin-angiotensin-aldosterone system [28, 29]. Because the plasma 
BNP level is correlated with the severity of cardiac dysfunction in patients with 
heart failure, BNP is used for diagnosis, stratification and monitoring of heart 
failure in clinical settings [30, 31]. BNP has also been demonstrated to be correlated 
with the Framingham Risk Score, which is an indicator for the risk of coronary 
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heart disease in the general population [32]. 
Troponin I is a protein expressed in myocardium constituting one of three 
subunits of troponins T, I and C [33]. Because cardiac troponin I (cTnI) is expressed 
as cardio-specific isoform in the myocardium, it is ideally suited for the detection of 
myocardial damage [34]. Due to the development of high sensitive troponin assays, 
the measurement of troponin for the diagnosis of acute coronary syndrome (ACS) is 
recommended as the most reliable biomarker [35, 36]. High sensitive troponin I 
assays have been shown to be elevated not only in patients with ACS but also those 
with chronic cardiovascular diseases including congestive heart failure. This is 
because high sensitive troponin I assays can detect small amount of cTnI in blood 
eluted from the myocardium by myocardial injury not only due to ischemic but also 
due to non-ischemic causes [37]. In fact, it has been shown to be useful not only for 
the diagnosis of ACS but also for predicting cardiovascular events such as 
congestive heart failure in patients with stable coronary artery disease [38] or 
pulmonary hypertension [39]. Zeller et al. showed that the high sensitive troponin I 
assay significantly improved the predictive values of cardiovascular events and 
coronary deaths in the general population over the contemporary troponin I assay  
[40]. 
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Due to the different release mechanisms of BNP and cTnI mentioned earlier, I 
assessed here whether a wider range of clinical and sub-clinical cardiovascular 
diseases could be detected by screening the general population with a combination 
of BNP and high sensitive troponin I assays [41]. The objectives of this study 
therefore will be as follows: 
1) To assess whether elevation of BNP or cTnI in the general population is 
associated with increased cardiovascular risks such as the diseases related to 
cardiovascular diseases and the Framingham risk factor. 
2) To determine whether BNP and cTnI complement with each other in detecting the 
broader range of high-risk populations. 
 
2. Materials and Methods 
 
1) Study Population  
952 subjects who visited Takeda Hospital Medical Examination Center for their 
annual health evaluation participated in this study. Upon excluding two subjects 
with the estimated glomerular filtration rate (eGFR) below 30 mL/min/1.73 m2, 
950 subjects were enrolled. 
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2) Study Design  
The study was designed to comply with the Declaration of Helsinki in 1964 and 
obtained approval of the Institutional Review Board at Takeda Hospital. Informed 
consent was obtained from each subject before the participation to the study. 
Adequate care was taken to ensure the protection of the privacy of each subject. 
 
3) Clinical Tests  
The clinical tests included body mass index (BMI), heart rate (HR), systolic and 
diastolic blood pressures (SBP and DBP), cardiothoracic ratio (CTR) determined 
by echocardiography and vital capacity (VC). Information about gender, age, 
medical history and smoking habit was collected from all subjects in interviews. 
 
4) Laboratory Tests  
All the blood samples were drawn in a sitting position in the morning after the 
subjects had been fasted since the previous night. All the subjects were evaluated 
with biochemistry and hematology tests as well as Architect STAT High Sensitive 
Troponin I (Abbott Laboratories, Illinois, USA) and Architect BNP-JP (Abbott 
34 
 
Laboratories, Illinois, USA) tests. The biochemistry test was performed on 
JCA-8060 (JEOL Ltd., Tokyo, Japan) that included albumin (ALB), aspartate 
aminotransferase (AST), alanine aminotransferase (ALT), gamma glutamyl 
transferase (GGT), uric acid (UA), creatinine (CRE), blood urea nitrogen (BUN), 
low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol 
(HDL-C), triglyceride (TG), hemoglobin A1c (HbA1c) and fasting blood glucose 
(FBG). The hematology test was performed on E-2100 (Sysmex Corporation, 
Kobe, Japan) that included white blood cell count (WBC), red blood cell count 
(RBC), hemoglobin (Hb), hematocrit (Ht) and platelet count (PLT). The eGFR 
was calculated according to the revised equations for the Japanese population as 
reported previously [42]. 
 
5) Calculation of the FRS  
The FRS was calculated according to the methods of D’Agostino et al [13]. 
 
6) Association with Diseases Related with Cardiovascular Risks  
I defined diseases related with cardiovascular risks that included hypertension, 
dyslipidemia, diabetes, chronic kidney disease (CKD) and hyper-uricemia 
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according to the following criteria. The presence of hypertension was defined 
when a subject was treated for the disease, the SBP was more than 139 mmHg or 
the DBP was more than 89. The presence of dyslipidemia was defined when a 
subject was treated for the disease or had steatosis, a high-density lipoprotein 
cholesterol (HDL-C) level less than 40 mg/dL, an LDL-C level more than 139 
mg/dL or a TG level more than 149 mg/dL. The presence of diabetes was defined 
when a subject was treated for the disease, had a fasting blood glucose (FBG) 
level more than 125 mg/dL or an HbA1c value more than 6.4%. The presence of 
CKD was defined when a subject was treated for the disease, had an eGFR less 
than 60 mL/min/1.73 m2 or had positive urine protein results. The presence of 
hyper-uricemia was defined when a subject was treated for the disease, had gout, 
or their uric acid (UA) level was more than 6.9 mg/dL. 
 
7) Comparisons of BNP-cTnI Quadrants  
Using the clinical cut-off values of BNP [43] and cTnI [44], I defined quadrants 
according to BNP and cTnI levels as follows: (i) Quadrant A: BNP level equal to 
or less than 40.0 pg/mL and cTnI level more than 26.2 pg/mL, (ii) Quadrant B: 
BNP level equal to or less than 40.0 pg/mL and cTnI level equal to or less than 
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26.2 pg/mL, (iii) Quadrant C: BNP level more than 40.0 pg/mL and cTnI level 
equal to or less than 26.2 pg/mL, (iv) Quadrant D: BNP level more than 40.0 
pg/mL and cTnI level more than 26.2 pg/mL. With these quadrants, I assessed 
factors that differentiated pairs of quadrants by performing Wilcoxon’s test. For 
the assessment, I chose age, BMI, SBP, HR, CTR, VC, Hb, PLT, UA, eGFR, BUN, 
LDL-C, HDL-C, TG, HbA1c, FBG as the candidate variables for cardiovascular 
risks. I also included the FRS to confirm whether quadrants A and C were 
associated with the FRS.  
 
8) Statistical Analyses  
JMP 11.0.0 (SAS) was used for the statistical analyses. The 95th percentiles of the 
distribution of BNP levels and the 99th percentiles of the distribution of cTnI 
levels in the population in this study were determined using the robust statistical 
method described in the Clinical & Laboratory Standards Institute (CLSI) 
document C28-A3c [45]. The differences of the basic characteristics by gender 
were assessed by Wilcoxon’s test. The associations of BNP or cTnI with the FRS 
were assessed by univariable followed by multivariable linear regression analyses 
in each gender. The associations of BNP or cTnI level with the diseases related 
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with cardiovascular risks were assessed by multivariable linear regression 
analyses. For these analyses, the presence or absence of a disease was encoded as 
“0 (absent)” or “1 (present).” 
 
3. Results 
 
1) Characteristics of the Subjects  
I summarized the background characteristics of the 950 subjects in Table 1. All 
the parameters were significantly different by gender except for the age, CTR, 
eGFR, LDL-C, HbA1c, and the presence of CKD.  
 
2) Association with the FRS  
The associations of the BNP or cTnI level with the FRS in each gender by the 
linear regression analyses were shown in Table 2. The BNP and cTnI levels were 
significantly and independently associated with the FRS in both genders.  
 
3) Association with Diseases Related with Cardiovascular Risks 
By the multivariable linear regression analyses, the presence of hypertension and 
38 
 
CKD were positively, but that of dyslipidemia was negatively associated with 
the BNP level, while the presence of hypertension and dyslipidemia were 
positively associated with the cTnI level (Table 3). 
 
4) Comparisons of BNP-cTnI Quadrants  
By the definition described in the Methods, I obtained 9, 932, 9 and 0 subjects in 
quadrant A, B, C and D, respectively (Fig. 1). I then assessed the differences 
between pairs of quadrants among quadrants A, B and C using Wilcoxon’s test 
(Table 4, Fig. 2). The BMI, CTR and the FRS were significantly higher in 
quadrant A than quadrant B. The age, CTR and the FRS were significantly 
higher and the PLT were significantly lower in quadrant C than quadrant B. 
Between quadrant A and C, the age was significantly lower, but the BMI and TG 
were significantly higher in quadrant A than those in quadrant C.  
 
4. Discussions 
In this study, I assessed the validity of the combination assay of BNP and cTnI 
for the screening of cardiovascular risks in the general population. In the 
background characteristics by gender, there were significant differences between the 
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gender (Table 1). As for most of the parameters related with cardiovascular risks 
including BMI, blood pressure, lipids and HbA1c, higher cardiovascular risks were 
indicated in the male group in comparison with the female group. The prevalence of 
the diseases related with cardiovascular diseases and the FRS were also higher in the 
male group. In consistent with these results, the cTnI level was higher in the male 
group as shown in previous reports [46, 47, 48]. The BNP level, on the contrary, was 
lower in the male group, which is consistent with the report by Kawai et al. [43]. 
Considering the result by Kawai et al. that the BNP level was negatively correlated 
with BMI [43], I thought the result in Table 1 that BMI was higher in the male group 
and the result in Table 3 that the BNP level was negatively correlated with 
dyslipidemia, were consistent.  
The result in Table 2 showed that the cTnI and BNP levels were positively and 
independently associated with the FRS. From this result, I think both cTnI and BNP 
are the indicators of risk for cardiovascular risk but they reflect different aspects of 
cardiovascular disorders.  
In Table 3, BNP was significantly correlated with hypertension, dyslipidemia 
and CKD, but the correlation with dyslipidemia was inversed. On the other hand, 
both hypertension and dyslipidemia were positively correlated with cTnI. I 
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understand this result as that hypertension is the common factor to elevate cTnI and 
BNP while dyslipidemia being the differentiating factor to decide whether cTnI or 
BNP is elevated.  
In Table 4 and Fig. 2, I characterized quadrants A, B and C. The result that 
quadrants A and C showed significantly higher CTR and FRS than quadrant B was 
thought to be one of the evidences to show the association of quadrants A and C 
with high cardiovascular risks. I interpreted the reason why BNP and cTnI were 
independently associated with the FRS as shown in Table 2 was because cTnI and 
BNP detect the two different populations (quadrant A and C). The factors that 
differentiated quadrants A and C were age and BMI. Together with the results in 
Table 3 that the BNP level was inversely associated with dyslipidemia while the TnI 
level was positively associated with, it could be assumed that obesity is a key factor 
that differentiates quadrants A and C. Because of the suppressed BNP level in 
quadrant A, the heart may be less protected due to attenuated cardio-protection by 
BNP and more susceptible to myocardial injury, giving ground to the TnI elevation. 
The result that the median of the age in quadrant A (59.0) was significantly lower 
than that in quadrant C (71.0) may indicate cardiac diseases related with 
dyslipidemia (e.g. atherosclerosis, angina pectoris, or myocardial infarction) develop 
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earlier in life than those without one. 
Taking all these results into consideration, I constructed a putative pathway of 
how these risk factors contribute in the elevation of BNP or cTnI level (Fig. 3). The 
idea is that hypertension is the common factor for the elevation of BNP and cTnI 
while dyslipidemia is a factor to differentiate the pathway of BNP or cTnI elevation, 
and CKD is a trigger for BNP elevation. From subject’s perspective, subjects with 
hypertension and dyslipidemia could develop myocardial injury as represented by 
the elevation of cTnI in their comparatively early age (e.g. in their 50’s) while 
subjects with hypertension but without dyslipidemia would evade developing 
myocardial injury and live longer but may develop cardiac hypertrophy as 
represented by the elevation of BNP in their elder age (e.g. in their 70’s). 
  
42 
 
Table 1. Background Characteristics of the Subjects.  
 
  
Unit Female (N = 439) Male (N = 511) P-value
Median (25%ile, 75%ile) Median (25%ile, 75%ile)
Age years 53.0 (46.5, 60.0) 54.0 (48.0, 61.0) 0.079
BMI kg/m2 21.4 (19.5, 23.5) 23.3 (21.6, 25.5) < 0.001
SBP mmHg 114.0 (103.0, 125.5) 120.0 (111.0, 132.0) < 0.001
DBP mmHg 72.0 (64.0, 81.0) 79.0 (71.0, 88.0) < 0.001
HR bpm 73 (67, 80) 70 (63, 78) < 0.001
CTR % 44.4 (41.3, 47.6) 44.7 (41.7, 47.5) 0.335
VC L 2.9 (2.5, 3.2) 4.1 (3.7, 4.5) < 0.001
WBC /uL 4800 (4000, 5600) 5300 (4450, 6350) < 0.001
RBC 104/uL 437 (417, 459) 483 (459, 510) < 0.001
Hb g/dL 13.1 (12.4, 13.6) 14.9 (14.2, 15.5) < 0.001
Ht % 40.1 (38.1, 41.6) 45.0 (43.0, 46.8) < 0.001
PLT 104/uL 23.6 (20.7, 26.6) 22.5 (19.4, 25.8) < 0.001
ALB g/dL 4.4 (4.3, 4.6) 4.5 (4.3, 4.7) < 0.001
AST U/L 20.0 (18.0, 24.0) 22.0 (18.5, 26.0) < 0.001
ALT U/L 17.0 (14.0, 22.0) 22.0 (17.0, 30.0) < 0.001
GGT U/L 18.0 (14.0, 24.5) 32.0 (22.0, 55.5) < 0.001
UA mg/dL 4.5 (3.9, 5.0) 6.1 (5.2, 6.8) < 0.001
eGFR mL/min/1.73 m2 70.8 (63.5, 79.6) 71.5 (65.1, 78.0) 0.792
BUN mg/dL 13.0 (11.0, 16.0) 14.0 (12.0, 16.0) < 0.001
LDL-C mg/dL 122.0 (102.5, 142.0) 125.0 (106.0, 146.0) 0.220
HDL-C mg/dL 76.0 (64.0, 87.0) 59.0 (50.0, 70.0) < 0.001
TG mg/dL 71.0 (55.0, 99.0) 102.0 (73.0, 146.5) < 0.001
HbA1c % (NGSP) 5.6 (5.5, 5.8) 5.7 (5.5, 5.9) 0.119
FBG mg/dL 95.0 (90.0, 100.0) 101.0 (95.0, 108.0) < 0.001
FRS 6.0 (3.0, 10.0) 10.0 (7.0, 13.0) < 0.001
CKD % 16.4 14.9 0.518
Dyslipidemia % 39.9 64.0 < 0.001
Hypertension % 22.8 38.6 < 0.001
Diabetes % 3.9 8.0 0.008
Hyper-uricemia % 0.9 22.1 < 0.001
Current smoker % 5.9 24.3 < 0.001
95%ile (95% CI) 95%ile (95% CI)
BNP pg/mL 23.1 (21.0, 28.9) 17.8 (15.6, 23.7) < 0.001
99%ile (95% CI) 99%ile (95% CI)
cTnI pg/mL 23.5 (11.5, 136.0) 26.8 (17.5, 65.2) < 0.001
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Table 2. Univariable and Multivariable Linear Regression Analyses for 
the Association of BNP or TnI with the FRS.  
 
  
Beta SE P-value Beta SE P-value
Females Intercept 5.969 0.284 < 0.001
BNP 0.095 0.024 < 0.001 BNP 0.088 0.023 < 0.001
cTnI 0.092 0.025 < 0.001 cTnI 0.083 0.025 < 0.001
Males Intercept 9.197 0.267 < 0.001
BNP 0.148 0.026 < 0.001 BNP 0.140 0.025 < 0.001
cTnI 0.157 0.038 < 0.001 cTnI 0.142 0.037 < 0.001
Univariable Multivariable
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Table 3. Multivariable Linear Regression Analyses for the association 
of BNP or cTnI with Diseases Related with Cardiovascular Risks.  
 
  
Beta SE P-value Beta SE P-value
Intercept 8.054 0.406 < 0.001 0.908 0.336 0.007
Hypertension 1.938 0.571 0.001 1.971 0.472 < 0.001
Dyslipidemia -2.347 0.533 < 0.001 1.081 0.441 0.014
Diabetes 0.845 0.880 0.338 -0.761 0.729 0.296
CKD 1.869 0.711 0.009 0.359 0.588 0.541
Hyper-uricemia -1.259 0.796 0.114 0.798 0.659 0.226
BNP cTnI
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Table 4. Assessment of Differentiating Factors Between Quadrants A, 
B and C.  
P-value less than 0.05 was shown in red. 
 
 
  
Quadrant A Quadrant B Quadrant C
N = 9 N = 932 N = 9
Median (25%ile, 75%ile) Median (25%ile, 75%ile) Median (25%ile, 75%ile) A vs. B B vs. C C vs. A
Gender - - - 0.915 0.915 1.000
Age 59.0 (56.0, 68.0) 54.0 (47.0, 60.0) 71.0 (68.0, 77.0) 0.120 < 0.001 0.047
BMI 25.6 (23.8, 25.8) 22.5 (20.6, 24.6) 20.1 (19.8, 24.5) 0.010 0.218 0.027
SBP 122.0 (115.0, 128.0) 117.0 (107.0, 128.0) 119.0 (113.0, 130.0) 0.466 0.407 0.965
HR 78.0 (63.0, 87.0) 71.0 (65.0, 79.0) 77.0 (72.0, 84.0) 0.560 0.242 0.860
CTR 46.3 (45.9, 49.1) 44.6 (41.5, 47.6) 47.2 (44.2, 53.6) 0.028 0.026 0.894
VC 3.5 (2.9, 4.0) 3.4 (2.9, 4.1) 3.7 (2.1, 3.9) 0.787 0.463 0.659
Hb 13.9 (13.9, 15.1) 14.0 (13.1, 15.0) 13.9 (12.8, 14.3) 0.759 0.636 0.689
PLT 22.2 (19.4, 23.6) 23.0 (20.2, 26.1) 18.9 (15.7, 20.0) 0.241 0.002 0.145
UA 6.1 (4.8, 6.7) 5.2 (4.4, 6.3) 5.7 (4.5, 6.3) 0.324 0.898 0.452
eGFR 73.9 (65.9, 81.3) 71.2 (64.6, 78.6) 65.7 (55.8, 77.2) 0.593 0.217 0.216
BUN 14.0 (13.0, 15.0) 14.0 (11.0, 16.0) 14.0 (13.0, 17.0) 0.585 0.368 0.789
LDL-C 124.0 (114.0, 135.0) 124.0 (104.0, 145.0) 114.0 (96.0, 126.0) 0.939 0.196 0.249
HDL-C 57.0 (54.0, 65.0) 67.0 (55.0, 80.0) 63.0 (56.0, 81.0) 0.081 0.876 0.250
TG 127.0 (75.0, 237.0) 86.0 (61.8, 124.3) 84.0 (61.0, 97.0) 0.057 0.390 0.038
HbA1c 5.8 (5.7, 6.0) 5.6 (5.5, 5.9) 5.7 (5.4, 5.7) 0.158 0.971 0.418
FBG 98.0 (96.0, 106.0) 97.0 (92.0, 105.0) 104.0 (95.0, 108.0) 0.446 0.222 0.724
FRS 12.0 (11.0, 14.0) 8.0 (6.0, 12.0) 13.0 (12.0, 17.0) 0.006 0.002 0.561
P-value
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Fig. 1: Graphical Representation of Two-dimensional Distribution of 
BNP and cTnI.  
Quadrants A, B, C and D are separated by cut-off of BNP (40 pg/mL) and that of cTnI 
(26.2 pg/mL). Quadrant A: upper left, quadrant B: lower left, quadrant C: lower right, 
and quadrant D: upper right. 
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Fig. 2: Graphical Representation of Wilcoxon’s Test Shown in Table 4.  
Factors (age, BMI, CTR, platelet count and FRS) in Quadrants A, B and C were 
assessed by Wilcoxon’s test. Blue bar: quadrant A. Red bar: quadrant B. Green bar: 
quadrant C. *: p-value < 0.05. **: p-value < 0.01. 
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Fig. 3: Speculated Pathway of the Biomarker-Elevation 
Schematic diagram to show the pathway of biomarker-elevation speculated from the 
results in Chapter 2.  
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Chapter 3.  Increased Levels of Cardiac Troponin I in Subjects 
with Extremely Low B-type Natriuretic Peptide 
Levels 
 
1. Introduction 
In Chapter 2, I have confirmed that BNP and cTnI detect populations with high 
cardiovascular risks in the general population and that BNP and cTnI detect 
non-overlapping two different high-risk populations at both wings of the 
characteristic “L-shaped distribution” in the 2D plot (Chapter 2, Fig. 1). In this 
Chapter, I examined whether BNP and cTnI influence each other in forming this 
distribution, especially as to whether elevation of cTnI level is associated with 
suppressed BNP level. 
The BNP cut-off level was reported at 18.4 pg/mL in 1993 [49], but 40 pg/mL 
was proposed in 2012 as an alternative cut-off for practical use in clinical settings 
[43]. In either case, there has been a basic understanding that lower BNP levels 
indicate better prognoses (Fig. 1). Among the numerous previous reports on BNP, I 
could not find any article that focused on the biological implications of extremely 
low BNP levels (e.g., BNP levels below 4 pg/mL), which I examined in this study.  
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As mentioned in Chapter 2, cTnI is expressed in the myocardium as a 
cardio-specific isoform, and thus it is ideally suited as a marker of myocardial 
damage [34]. Owing to the development of high sensitive troponin assays in recent 
years, the measurement of troponin levels with those assays for the diagnosis of 
acute coronary syndrome (ACS) is stipulated as more reliable than measurements 
with any other conventional biomarkers based on latest guidelines [35, 36]. High 
sensitive cTnI assays such as the one used in this study are not only used for the 
diagnosis of ACS but also known to have the ability to predict cardiovascular 
events in the general population. By measuring cTnI levels with the high sensitive 
cTnI assay in a Scottish cohort consisting of 15,340 individuals from the general 
population, Zeller et al. showed that cTnI was associated with future cardiovascular 
events over an average of 20 years of follow-up and suggested threshold values of 
4.7 pg/mL for women and 7.0 pg/mL for men to identify individuals at risk of 
future cardiovascular events [40]; these results suggested threshold values are far 
below the 99th percentiles of cTnI concentrations shown in the package insert of 
the assay – 15.6 pg/mL for women and 34.2 pg/mL for men.  
In a 10-year follow-up of the Inter99 study, Hansen et al. showed with a cohort 
of 6,238 general population that metabolically healthy obese subjects had a higher 
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risk of ischemic heart disease (IHD) than metabolically healthy subjects with 
normal weight [50]. As shown by several reports, BNP level is reduced in 
individuals with obesity independent of the presence or absence of cardiac diseases 
[51-53]. The metabolically healthy obese subjects in the Inter99 Study are therefore 
considered to be equivalent to individuals with reduced BNP levels. Because of the 
cardio-protective effects exerted by BNP, Tsutsumi et al. hypothesized that the 
increased risk of IHD in individuals with obesity is due not only to well-known risk 
factors (e.g., hypertension, dyslipidemia, diabetes) but also to the compromised 
cardio-protection of the reduced BNP level as shown in Fig. 2 [54]. By a covariance 
structure analysis in 1,252 patients with cardiac disorders, they confirmed that low 
BNP level, as well as hypertension, dyslipidemia and haemoglobin A1c (HbA1c), 
but not body mass index (BMI) was significantly associated with the incidence of 
IHD (p < 0.001) [54]. To confirm this hypothesis further, I assessed whether low 
BNP level was associated with an enhanced cardiovascular risk in the general 
population in this study by using cTnI as an indicator of cardiac disorders [55]. 
 
2. Materials and Methods 
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1) Study Population  
I conducted this study in collaboration with Takeda Hospital Medical 
Examination Center and Niigata Medical Association of Occupational Health. 
The study protocol conformed to the ethical guidelines of the 1975 Declaration 
of Helsinki and was approved by the Takeda Hospital Institutional Review 
Board and the Ethics Committee at Niigata Medical Association of Occupational 
Health. Upon obtaining informed consent, I recruited 2,005 subjects older than 
38 years who visited Takeda Hospital Medical Examination Center or Niigata 
Medical Association of Occupational Health for their annual health check-up 
and showed no apparent symptoms of cardiac disease during doctor interviews. 
Among the recruited subjects, I excluded subjects with outlying laboratory test 
results by Dixon’s method [23] and subjects with an eGFR below 30 
mL/min/1.73 m2. This resulted in the exclusion of one subject who exhibited an 
extremely high cTnI level (826.1 pg/mL) and three subjects who exhibited 
eGFR below 30 mL/min/1.73 m2, corresponding to the enrolment of 2,001 
subjects (884 females and 1,117 males) in total. 
 
2) Clinical and Laboratory Tests 
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All subjects underwent routine biochemical and hematological analyses for 
their health check-ups. BNP level was measured by an ARCHITECT BNP-JP 
assay (Abbott Laboratories, Abbott Park, IL, USA). According to the package 
insert of the BNP assay, the analytical sensitivity, which is defined as the 
concentration of the mean of the blank + 2SD, was 5.8 pg/mL. cTnI level was 
measured with an ARCHITECT STAT High Sensitive troponin I assay (Abbott 
Laboratories, Abbott Park, IL, USA) [44]. According to the package insert of the 
cTnI assay, the 99th percentile of cTnI level in an apparently healthy population 
was 26.2 pg/mL, the LoD was 1.9 pg/mL, and the CV% at the 99th percentile 
was 4.0%. All blood samples were drawn from participants in a sitting position 
on the following morning after they had fasted overnight. BMIs were calculated 
based on the subjects’ heights and weights. The information regarding gender, 
age, medical history and smoking habits was collected from interviews. The 
estimated glomerular filtration rate (eGFR) was calculated using equations for 
the Japanese population, as reported previously [42]. The Framingham Risk 
Score was calculated according to the D’Agostino’s formula [13]. 
Chronic kidney disease (CKD) was defined as present when a subject was 
under treatment for the disease, had an eGFR less than 60 mL/min/1.73 m2 or 
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had positive urine protein results. Dyslipidaemia was defined as present when a 
subject was under treatment for the condition, had steatosis, had a high-density 
lipoprotein cholesterol (HDL-C) level lower than 40 mg/dL, had a low-density 
lipoprotein cholesterol (LDL-C) level higher than 139 mg/dL or had a 
triglyceride (TG) level higher than 149 mg/dL. Hypertension was defined as 
present when a subject was under treatment for the condition, had a systolic 
blood pressure (SBP) higher than 139 mmHg or had a diastolic blood pressure 
(DBP) higher than 89 mmHg. Diabetes was defined as present when a subject 
was under treatment for the disease, had a fasting blood glucose (FBG) level 
higher than 125 mg/dL or had an HbA1c value (NGSP) higher than 6.4%. 
 
3) Validation of the BNP Assay 
To assess the lowest quantifiable BNP level of the BNP assay used here, I 
performed a reproducibility test with serially diluted samples. The samples were 
prepared by serially diluting Control L (BNP = 54.2 pg/mL) with Calibrator A 
(BNP = 0.0 pg/mL), which are components of the BNP assay, by twofold down 
to BNP level below 1 pg/mL. The reproducibility test was performed by 
repeating the measurements ten times for each sample. I defined the LoQ as the 
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lowest BNP concentration for which the total error, defined as the sum of the 
CV% and absolute bias, was equal to or less than 30% based on reports in the 
literature [25]. The absolute bias was defined as the absolute value of the bias, 
which was the percentage of deviation of the measured value from the expected 
value. 
 
4) Metabolic Derangement in the Low BNP Subgroups 
To evaluate the presence of metabolic derangement in patients with extremely 
low BNP levels, I investigated the percentage of subjects who exceeded the 
ULN WC or BMI in the low BNP subgroups. According to the report from the 
Japan Society for the Study of Obesity, 90 cm for women and 85 cm for men 
were used as the ULN for WC and 25 kg/m2 was used as the ULN for BMI [56]. 
The low BNP subgroups were obtained from the total cohort by limiting the 
maximum BNP level to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15 or 20 pg/mL. 
 
5) Statistical Analyses 
I used JMP 11.0.0 (SAS Institute Inc., Cary, NC, USA) for multivariate 
analyses. To analyze the factors that contributed to the elevation of cTnI level, I 
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used IBM SPSS Amos (IBM, Armonk, New York, USA) to perform covariance 
structure analysis by fitting the data into structural equation models (SEM), with 
which one of my collaborators, Professor Yoshimura at the Jikei University, had 
successfully elucidated the relationship among factors involved in 
cardiovascular pathogenesis [54, 57-61]. For the analyses, I converted BNP and 
cTnI into log(BNP) and log(cTnI) respectively because the distributions were 
non-Gaussian when confirmed by Shapiro-Wilk tests. For the purpose of the 
analyses, I assigned cTnI values lower than 0.1 pg/mL to 0.05 pg/mL. For the 
assessment of the parameters that contributed to cTnI elevation, I chose 
log(BNP), gender, age, BMI, SBP, eGFR and Hb as the possible risk factors and 
categorized the rest of the factors into e1. 
To assess the mechanism by which cTnI levels were associated with BNP 
levels in the low BNP subgroups, I defined the subgroups among the overall 
population by limiting the maximum BNP level to cut-off values of 1, 2, 3, 4, 5, 
6, 7, 8, 9, 10, 15 and 20 pg/mL and performed covariance structure analyses for 
each subgroup. P values of < 0.05 were considered as statistically significant. 
 
3. Results 
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1) Characteristics of the Study Population 
The characteristics of the total cohort (884 females and 1,117 males) are 
presented in Table 1. Briefly, the median values of the age, BMI, BNP level and 
cTnI level of the subjects were 56.0 years, 22.6 kg/m2, 5.6 pg/mL and 1.5 pg/mL, 
respectively. The median Framingham Risk Score was 10.0, which meant a 
6.3% 10-year cardiovascular risk for the women and a 9.4% risk for the men 
according to a previous report [13].  
 
2) Analytical Performance of the BNP Assay  
I performed a reproducibility test for the BNP assay used in this study and 
assessed the limit of quantitation (LoQ) as described in Materials and Methods. 
As shown in Table 2, the total error, defined as the sum of the coefficient of 
variation (CV%) and absolute bias, was within 30% when assessed with serially 
diluted samples of BNP levels ranging from 0.8 pg/mL to 54.2 pg/mL. From this 
result, the LoQ of the BNP assay was determined to be 0.8 pg/mL.  
 
3) Two-dimensional Distribution of BNP and cTnI 
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A two-dimensional distribution chart was constructed by plotting BNP level on 
the X-axis and cTnI level on the Y-axis for the total cohort (N = 2,001) as 
illustrated in Fig. 3. The correlation coefficient of the linear regression of the 
distribution was 0.096 (p < 0.001), and the regression formula was Y = 0.090X + 
0.239. 
 
4) Metabolic Derangement in the Low BNP Subgroups 
To evaluate the presence of metabolic derangement in patients with extremely 
low BNP levels, I determined the percentage of subjects who exceeded the upper 
limit of normal (ULN) WC or BMI. As shown in Fig. 4, drastic increases in the 
percentage of subjects exceeding the ULN WC and BMI were seen in subgroups 
with BNP levels lower than 4 pg/mL. 
 
5) Covariance Structure Analyses  
I performed covariance structure analyses with the 12 low BNP subgroups with 
the upper limits of BNP levels at 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15 or 20 pg/mL. The 
numbers of subjects in these subgroups were 81, 287, 516, 730, 918, 1,070, 
1,205, 1,329, 1,416, 1,490, 1,747 and 1,860, respectively. The covariance 
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structure analyses were performed to assess factors associated with elevated 
log(cTnI) within these subgroups. The beta value between log(BNP) and 
log(cTnI) levels was negative (-0.29) in the subgroup with the BNP cut-off 
levels at 1 pg/mL (Fig. 5a, N = 81) but positive (0.04) in the subgroup with the 
BNP cut-off level at 20 pg/mL (Fig. 5b, N = 1,860). Fig. 6 shows the plots of 
beta values of all the subgroups in the Y-axis against BNP cut-off levels in the 
X-axis. A sharp drop in the beta value was observed as the BNP cut-off level 
decreased from 20 pg/mL to 1 pg/mL. In particular, the beta values for the 
subgroups with BNP cut-off levels at 1, 2, and 3 pg/mL demonstrated strong 
significance (p < 0.005). 
 
6) Multivariate Analyses  
To evaluate the contribution of obesity to the elevation of cTnI level, I 
performed multivariate analyses for log(cTnI) with the total cohort and with the 
subgroup with BNP level lower than 4 pg/mL (Table 3). In similar to the results 
of the covariance structure analyses, the coefficient of log(BNP) against 
log(cTnI) in the subgroup with BNP level lower than 4 pg/mL was inversed 
(-0.423), whereas it was positive (0.149) in the total cohort. In the subgroup with 
60 
 
BNP level lower than 4 pg/mL, BMI was not significantly associated with 
log(cTnI).  
 
4. Discussions 
In this study, I confirmed that BNP was positively correlated with cTnI in the 
total cohort (Fig. 3) and that this positive correlation was maintained in the group 
with the BNP cut-off level at 20 pg/mL (Fig. 5b). I think that this is consistent with 
previous reports that showed the elevation of cTnI in subjects with chronic cardiac 
diseases, including congestive heart failure, left ventricle hypertrophy, and 
cardiomyopathy [37], in which case BNP level is usually elevated, as well as the 
elevation of BNP in subjects with acute myocardial infarction [62], in which case 
cTnI level is usually elevated. 
Regarding the BNP assay that I employed in this study, 5.8 pg/mL was the 
lowest measurable BNP concentration according to the package insert. For the 
purpose of this study, however, I confirmed that the LoQ was 0.8 pg/mL by the 
definition described in Materials and Methods (Table 2). I then proceeded to define 
the subgroups with BNP cut-off levels as low as 1 pg/mL, which provided a basis 
for the breakthrough in elucidating the pathogenic role of low BNP level. By 
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performing covariance structure analyses using subgroups with BNP cut-offs equal 
to or lower than 20 pg/mL, I confirmed that the beta values of log(BNP) against 
log(cTnI) decreased as the BNP cut-off levels decreased from 20 pg/mL to 1 pg/mL, 
and the inverse correlation became significant (p < 0.005) at BNP cut-off levels 
lower than 4 pg/mL (Fig. 6). From these results, I concluded that subjects with BNP 
levels lower than 4 pg/mL were susceptible to myocardial injury due to decreased 
BNP level. These results are consistent with the findings of the previous report by 
Tsutsumi et al. that low BNP level was significantly associated with the incidence of 
IHD (p < 0.001) [54] and support the hypothesis that insufficient BNP level may 
play a pathogenic role in the occurrence of cardiac disorders. 
Notably, the association between BMI and log(cTnI) in the low-BNP group 
was not significant (Table 3 and 4). Because increased BMI is reported to be 
associated with reduced BNP level [51-53], the inverse association between cTnI 
and BNP may indicate that cTnI elevation did not directly result from reduced BNP 
level but rather from increased BMI, which coincidentally reduced BNP level. 
However, the results demonstrated that the elevation in log(cTnI) was inversely and 
directly associated with BNP but not with BMI in the low-BNP group (Table 3 and 
4), whereas the elevation in log(cTnI) was positively associated with both BNP and 
62 
 
BMI in the control group (Table 3 and 5). This result is consistent with the previous 
report that obesity contributes to the incidence of IHD via low BNP levels [54].  
Pleiotropic cardio-protective effects exerted by BNP have been reported by 
several researchers [63]. These effects include natriuresis, diuresis, vasodilation, 
lusitropy, lipolysis, weight loss and improved insulin resistance. As mentioned 
earlier, BNP level is reduced in individuals with obesity, but BNP affects weight loss 
in turn, indicating the presence of a balance between the effect of obesity to reduce 
BNP level and the effect of BNP to improve obesity. As Inoue et al. reported earlier, 
BNP level was also inversely associated with insulin resistance in patients with heart 
failure [64]. Therefore, a similar balance may exist between the effect of insulin 
resistance to reduce BNP level and the effect of BNP to improve insulin resistance. 
In this regard, a subject with low BNP level is at a status in which the effect of 
obesity or insulin resistance is dominant over the effect of BNP to improve obesity 
or insulin resistance. Under this circumstance, the cardio-protective effects of BNP, 
such as natriuresis, diuresis, vasodilation, or lusitropy, could be compromised, 
making the subject prone to myocardial injury.  
In addition to the obesity and insulin resistance, genetic factors should also be 
taken into consideration as factors for reduced BNP levels. Polymorphism in the 
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gene encoding BNP, natriuretic peptide precursor B (NPPB), has been reported to 
affect BNP expression levels [65]. As for polymorphisms in NPPB at T-381C, BNP 
level resulting from the genotype TT is lower than that resulting from the genotype 
TC or CC [64]. Seidelmann et al. reported that a polymorphism at the NPPB 
promoter, rs198389, was associated with the expression of NT-proBNP [66]. In that 
report, the authors showed that NT-proBNP expression, presumably BNP expression 
as well, was lower in subjects with the genotype AA at rs198389 than in subjects 
with the genotype AG or GG22. I, therefore, assume that low BNP levels result from 
a combination of factors including obesity, insulin resistance, and polymorphisms at 
NPPB and its promoter. 
It is interesting that the slope of the curve shown in Fig. 6 looks biphasic; the 
slope is nearly horizontal when the BNP cut-off level is higher than 4 pg/mL, 
whereas the slope is precipitous at BNP cut-off levels lower than 4 pg/mL. This 
pattern may be reflective of a mechanism that compensates for the pathogenic effect 
of insufficient BNP level – a physiological mechanism that compensates for the 
compromised cardio-protective effect of the insufficient BNP level to attenuate 
injury to the cardiomyocytes, in a manner similar to the mechanism observed in the 
compensated status in patients with heart failure [67]. 
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Regarding the subject with a high cTnI level (826.1 pg/mL) who was excluded 
from this study as mentioned in Materials and Methods, the BNP level was only 1.9 
pg/mL. This subject may also be another example of a case with cTnI elevation 
under low BNP conditions. 
One of the reasons why it was possible for us to identify the pathogenic effect 
of low BNP level was that I performed the assessment in the general population, 
rather than clinical patients. As mentioned earlier, it is known that BNP is expressed 
not only in patients with heart failure but also in patients with acute myocardial 
infarction [62]. Therefore, it would have been very difficult for us to identify 
subjects with BNP levels as low as those observed in the population in this study if I 
had chosen clinical patients with cardiac diseases as the study subjects. However, 
the putative mechanism by which a BNP level lower than that physiologically 
required exerts a pathogenic effect could be generalized to patients with cardiac 
diseases if, via the determination of influences of factors that suppress BNP 
expression (e.g., high BMI, insulin resistance, and genetic factors), I can assess 
whether BNP level in those patients are lower than physiologically required. If this 
becomes possible, the monitoring of BNP level would be greatly beneficial for 
patients with cardiac diseases as well as for the general population.   
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Table 1: Basic Characteristics of the Total Cohort.  
 
 
Unit
N = 2,001
(884 females and 1,117 males)
Median (25%ile, 75%ile)
Age years 56.0 (48.0, 63.0)
BMI kg/m2 22.6 (20.6, 24.8)
WC kg/m2 81.5 (75.7, 87.5)
SBP mmHg 119.0 (109.0, 129.0)
DBP mmHg 76.0 (68.0, 84.0)
Heart Rate bpm 67.0 (61.0, 75.0)
Vital Capacity L 3.4 (2.8, 4.1)
WBC /L 5200.0 (4300.0, 6100.0)
RBC 104/L 462.0 (433.0, 491.0)
Hb g/dL 14.2 (13.3, 15.2)
Ht % 43.0 (40.5, 45.6)
PLT 104/L 23.6 (20.6, 27.3)
ALB g/dL 4.4 (4.2, 4.6)
AST U/L 21.0 (18.0, 25.0)
ALT U/L 19.0 (14.0, 26.0)
GGT U/L 26.0 (17.0, 45.0)
UA mg/dL 5.2 (4.3, 6.2)
eGFR mL/min/1.73 m2 75.3 (67.5, 84.8)
BUN mg/dL 13.0 (11.0, 16.0)
LDL-C mg/dL 124.0 (106.0, 144.0)
HDL-C mg/dL 62.0 (51.0, 75.0)
TG mg/dL 88.0 (62.0, 130.0)
HbA1c % (NGSP) 5.6 (5.4, 5.9)
Fasting Blood Glucose mg/dL 98.0 (92.0, 106.0)
Framingham Risk Score 10.0 (7.0, 14.0)
BNP pg/mL 5.6 (3.0, 10.3)
cTnI pg/mL 1.5 (0.6, 2.8)
Current smoker % 35.6
CKD % 10.4
Dyslipidaemia % 65.3
Hypertension % 33.4
Diabetes % 32.2
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Table 2: Evaluation of the Quantifiable Range of the BNP Assay.  
The samples were prepared by diluting Control L by dilution factors signified at the top 
row.  
Dilution factor 
N Unit Blank 64  32 16 8  4  2  
Cont. 
L 
1 pg/mL 0.0 0.9 1.5 3.3 6.3 14.6 28.6 60.7 
2 pg/mL 0.0 0.8 1.9 3.0 6.7 14.0 27.4 53.8 
3 pg/mL 0.0 1.0 1.8 3.3 6.5 14.2 26.6 55.2 
4 pg/mL 0.0 0.8 1.5 3.2 6.2 13.5 27.1 52.6 
5 pg/mL 0.0 0.7 1.6 3.1 6.4 13.3 28.2 55.3 
6 pg/mL 0.0 0.7 1.5 3.2 6.8 13.3 27.2 52.3 
7 pg/mL 0.0 0.7 1.3 3.3 6.4 13.1 28.4 56.2 
8 pg/mL 0.0 0.7 1.6 3.5 6.7 13.0 25.9 49.8 
9 pg/mL 0.0 0.6 1.7 3.2 6.3 13.3 27.3 54.3 
10 pg/mL 0.0 0.6 1.6 3.1 6.6 13.0 26.2 52.1 
Expected value 
(mean) 
pg/mL 0.0 0.8 1.7 3.4 6.8 13.6 27.1 54.2 
Measured value 
(mean) 
pg/mL 0.0 0.8 1.6 3.2 6.5 13.5 27.3 54.2 
Bias (%) % - -10.3 -4.4 -4.8 -4.3 -0.3 0.7 0.0 
CV% % - 16.7 11.4 3.9 3.0 4.1 3.4 5.4 
Abs(bias)%+CV% % - 27.0 15.8 8.8 7.3 4.4 4.0 5.4 
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Table 3: Multivariate Analysis against Log(cTnI) in the Total Cohort 
and a Subgroup with BNP Level Lower than 4 pg/mL.  
 
Total Cohort BNP Level Lower Than 4 pg/mL 
  Coefficient SE T p-value  Coefficient SE t p-value 
Intercept -2.698  0.221  -12.23 < 0.001 -2.647  0.529  -5.01  < 0.001
Log(BNP) 0.149  0.038  3.91 < 0.001 -0.423  0.130  -3.24  0.001 
Gender 0.281  0.036  7.77 < 0.001 0.309  0.085  3.62  < 0.001 
Age 0.020  0.002  12.91 < 0.001 0.021  0.004  5.69  < 0.001
BMI 0.015  0.005  3.23 0.001 0.008  0.010  0.76  0.446 
SBP 0.003  0.001  3.67 < 0.001 0.005  0.002  2.03  0.043 
Hb 0.015  0.013  1.13 0.260 0.015  0.032  0.46  0.647 
eGFR 0.005  0.001  4.94 < 0.001  0.005  0.002  2.35  0.019 
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Table 4: Estimation with Structural Equation Model against Log(TnI) 
in the Group of Subjects with BNP Values Equal to or Less Than 1 
pg/mL. 
 
Clinical 
Factor 
  Estimate SE Test 
statistic
p-value Standard  
regression 
coefficient 
Log(cTnI)        
 ← Gender 0.408 0.256 1.597 0.110 0.408  
 ← Age 0.018 0.010 1.701 0.089 0.018  
 ← eGFR 0.003 0.005 0.501 0.616 0.003  
 ← SBP 0.011 0.007 1.568 0.117 0.011  
 ← Log(BNP) -1.186 0.436 -2.718 0.007 -1.186  
 ← BMI 0.022 0.026 0.825 0.409 0.022  
 ← Hb -0.176 0.087 -2.032 0.042 -0.176  
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Table 5: Estimation with Structural Equation Model against Log(TnI) 
in the Group of Subjects with BNP Values Equal to or Less Than 20 
pg/mL. 
 
Clinical 
Factor 
  Estimate SE Test 
statistic
p-value Standard  
regression 
coefficient 
Log(cTnI)        
 ← Gender 0.270 0.038 7.111 <0.001 0.270  
 ← Age 0.021 0.002 12.549 <0.001 0.021  
 ← eGFR 0.005 0.001 4.933 <0.001 0.005  
 ← SBP 0.004 0.001 3.880 <0.001 0.004  
 ← Log(BNP) 0.085 0.044 1.914 0.056 0.085  
 ← BMI 0.012 0.005 2.470 0.014 0.012  
 ← Hb 0.017 0.014 1.245 0.213 0.017  
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Fig. 1: BNP as a Biomarker for Heart Failure 
Schematic diagrams to show why BNP can be used as a biomarker for heart failure by 
contrasting the amount of BNP secretion in healthy subjects (upper diagram) against 
subjects with heart failure (lower diagram).  
 
 
 
  
Heart BNP
Heart BNP
Certain amount of BNP is secreted in blood in healthy subjects.
The amount of BNP secretion increases when the heart wall becomes thicker 
(hypertrophy) by heart failure. Therefore, BNP is used as a clinical test for the diagnosis 
and monitoring of heart failure.
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Fig. 2: BNP as a Physiologically Active Substance 
Schematic diagrams to show functions of BNP when BNP is viewed as a 
physiologically active substance by contrasting functions in healthy subjects (upper 
diagram) against subjects with reduced BNP level such as by obesity (lower diagram). 
 
 
  
BNP reduces burden on the heart by exerting physiological effects shown as above.
（RAA System: Renin-Angiotensin-Aldosterone System
VasodilatationNatriuresis Regulation RAA System*
BNP
Is the heart properly protected in an internal environment where BNP level is 
reduced such as in a subject with obesity?
Obesity, etc.
BNPHeart
Heart
VasodilatationNatriuresis Regulation RAA System
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Fig. 3: Two-dimensional Plot of BNP (X-axis) and cTnI (Y-axis) Levels 
of the Total Cohort.  
The solid line (    ) signifies linear regression. The red dotted line (    ) signifies the 
99th percentile cut-off level of cTnI, 26.2 pg/mL.  
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Fig. 4: Increased Percentage of Obesity in Low-BNP Subgroups.  
Percentages of subjects exceeding the upper limit of normal (ULN) values of WC or 
BMI (Y-axis) in subgroups defined by the maximum BNP level shown in the X-axis.  
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Fig. 5a: Path Diagram against Log(cTnI) in Subjects with BNP Levels 
Equal to or Lower Than 1 pg/mL (Low BNP Group, N = 81).  
The coefficient of standardized regression () of each path is shown adjacent to the path. 
P-values are also shown in parentheses regarding the direct association between 
log(cTnI). 
 
 
  
Gender
Age
eGFR
SBP
Log(BNP)
BMI
Hb
Log(cTnI)
e1
0.24 (0.110)
0.19 (0.089)
0.05 (0.616)
0.19 (0.117)
-0.29 (0.007)
0.11 (0.409)
-0.32 (0.042)
0.19
-0.34
-0.14
0.05
-0.17
0.26
0.69
-0.03
0.20
0.01
-0.01
-0.10
0.06
0.01
0.02
-0.13
0.45
-0.33
0.28
-0.12
0.52
-0.19
 (p-value)
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Fig. 5b: Path Diagram against Log(cTnI) for Subjects with BNP Levels 
Equal to or Lower Than 20 pg/mL (Control Group, N = 1,860).  
The coefficient of standardized regression () of each path is shown adjacent to the path. 
P-values are also shown in parentheses regarding the direct association between 
log(cTnI). 
 
 
  
Gender
Age
eGFR
SBP
Log(BNP)
BMI
Hb
Log(cTnI)
e1
0.20 (< 0.001)
0.28 (< 0.001)
0.11 (< 0.001)
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0.04 (0.056)
0.06 (0.014)
0.04 (0.213)
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-0.19
0.15
0.27
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0.02
-0.03
0.02
-0.07
-0.05
0.32
-0.26
0.25 -0.13
0.34
0.07
 (p-value)
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Fig. 6: Inversed Correlation Between between Log(BNP) and 
Log(cTnI) in Low-BNP Subgroups.  
Betas between log(BNP) and log(cTnI) in Low-BNP subgroups defined by the 
maximum BNP levels were plotted in X-axis against the maximum BNP levels in 
Y-axis. The red diamonds (  ) signify beta values with p-values less than 0.005. The 
dotted line signifies level of beta equals zero.  
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Fig. 7: Speculated Subsequence of Reduced BNP 
From the result that BNP is inversely associated with cTnI, the cardio-protective effect 
by BNP is speculated to be compromised in subjects with suppressed BNP level such as 
by obesity (lower diagram) when contrasted with the cardio-protective effect exert by 
BNP in healthy subjects (upper diagram), which could bring about myocardial injury 
represented by the elevation of cTnI.  
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Chapter 4. Concluding Remarks 
 
1. Summary 
In Chapter 1, I evaluated the 13 biomarkers related with cardiovascular 
diseases in terms of their clinical specificity, utility for diagnosis, assessment of 
disease severity, monitoring of the treatment and assessment of prognosis. From this 
evaluation, BNP and cTnI resulted in the two best biomarkers (Chapter 1, Table 3). I, 
therefore, setup the objectives of this study,  
1) to assess whether BNP or cTnI shows association with the risk factors for 
cardiovascular diseases,  
2) to assess whether BNP and cTnI detect different populations and different 
(sub-clinical) cardiovascular diseases, and 
3) to assess whether there is any positive or inverted association between BNP and 
cTnI. 
In Chapter 2, I measured BNP and cTnI levels in 950 subjects (439 females 
and 511 males) who came to have annual health checkup to the checkup centers. 
Here, I have confirmed that BNP and cTnI detect populations with high 
cardiovascular risks in the general population and that BNP and cTnI detect 
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non-overlapping two different high-risk populations shown as the characteristic 
“L-shaped distribution” in the 2D plot (Chapter 2, Fig. 1). 
In Chapter 3, I assessed with 2,001 general population (884 females and 1,117 
males) whether elevated cTnI levels are more frequent in the subgroup with 
extremely low BNP as indicated by the “L-shaped distribution” by employing the 
covariance structure modeling analyses. The analyses showed significant inversed 
association between log(BNP) and log(cTnI) in the subgroups with the BNP levels 
lower than 4pg/mL (Chapter 3, Fig. 5a and 6). This result indicated that 
cardio-protective effect of BNP could be compromised at the extremely low BNP 
level (e.g. < 4 pg/mL) so that cTnI levels are more frequently elevated by the 
myocardial injury as the consequence.  
Fig. 1 shows the consolidation of the results obtained in this study; quadrants 
A and C that are two independent populations high in cardiovascular disease risk 
confirmed in Chapter 2, and a population with extremely low BNP which has 
potential risk of cTnI elevation indicated in Chapter 3. 
In conclusion, both BNP and cTnI are necessary for the screening of potential 
cardiovascular diseases because they detect different high-risk populations. 
Furthermore, there may be potential risk for the myocardial injury by the 
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compromised cardio-protective effect by BNP in the sub-population with extremely 
low BNP. 
 
2. Limitations of this study 
This study has the following limitations. Although the total numbers of 
subjects were high (950 in Chapter 2 and 2,001 in Chapter 3), the percentage of the 
subjects with cTnI level greater than the 99th percentile (26.2 pg/mL) was only 
1.3% (27 subjects) and that of the subjects with BNP level greater than 40 pg/mL 
was only 1.5% (30 subjects), and thus, the bias in the population may have affected 
the results. The other limitation is that the range of the parameters of health status 
in this population was comparatively narrow; for example; the BMI was within 
20.6 and 24.8 in 50% of the population. Therefore, slight deviations from the 
overall population (e.g., subjects with extremely high BMI) may have affected the 
results. Last but not least, although the conclusion that extremely low BNP level is 
one of the causes for the development of cardiovascular diseases is consistent with 
previous reports (e.g., obesity is associated with higher IHD risk; low BNP is 
associated with the incidence of IHD; elevated cTnI level is associated with 
cardiovascular risks in the general population), I do not have prospective and direct 
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evidence yet, which need to be obtained in the future. 
 
3. Future prospective 
To establish this screening method, I think it has to be validated from at least 
the following aspects; 
1) the assessment of the prospective outcome with subjects exceeding cTnI cut-off 
who belong to quadrant A of Fig. 1 in Chapter 2 and subjects exceeding BNP 
cut-off who belong to quadrant C of Fig. 1 in Chapter 2, 
2) the identification of pathogenic lesion in quadrants A and C, 
3) the consensus on further medical examinations to be performed when a subject 
shows elevated cTnI or BNP, 
4) the determination of optimal cut-off levels and frequency of this combination 
assay to be performed (e.g. once a year, once another year) for the prevention of 
cardiac sudden death, and 
5) the cost-benefit analysis.  
Once this screening system is established, the number of the test is expected to 
increase to reach, eventually, to the number of the total population above 40 years 
old, which is approximately 60 million in Japan. Assuming 1% of BNP-high and 
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1% of cTnI-high populations, there will be 1.2 million who will be subjected to 
further examinations and necessary treatments. Considering the annual cardiac 
sudden death in Japan, 30,000 to 40,000, I believe this screening would 
substantially reduce the number of the sudden deaths. 
In this study, I selected BNP and cTnI as the two best cardiac biomarkers for 
the screening of potential cardiovascular diseases in the general population. 
Because these biomarkers are directly associated with the cardiac damages, the risk 
stage could be differentiated from the risk stage indicated by the conventional risk 
factors (e.g. hypertension, dyslipidemia, smoking, diabetes, CKD). Here I propose a 
concept of differentiated risk stages. The risk stage indicated by the elevation of 
either cTnI or BNP is considered as progressed when compared with the risk stage 
indicated by the presence of the conventional risk factors because the conventional 
risk factors are the factors that could cause myocardial damages in the future 
whereas the elevation of cTnI or BNP indicates that myocardial damages are 
present (Fig. 2).  
In a rapidly aging society like Japan, I believe early detection of diseases for 
the early intervention would greatly help extending the healthy life activating the 
society by the increased the ratio of productive population. 
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The concept of differentiated risk stages could be applied not only to the 
cardiovascular diseases but also to the oncology area, for example. As shown in Fig. 
3, factors such as smoking, western diet, obesity, toxic chemicals, insult to immune 
function could be the indicators for the early risk stage, while transformation of cell 
phenotypes or functions such as constitutive signaling for cell growth, 
anti-apoptotic ability, unresponsiveness to cell-to-cell contact inhibition, ability to 
inactivate immunity, secretion of growth factors, or ability for cell adhesion and 
infiltration are considered to be the indicators for the advanced risk stage. Human 
epididymis protein 4, or HE4, could be the candidate biomarker to indicate the 
advanced risk stage because HE4 has been shown to enhance tumor growth and 
promote cell adhesion and infiltration [68, 69]. 
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Fig. 1: Summary of High Risk Groups 
Schematic diagram to show the groups of high cardiovascular risks indicated in Chapter 
2 and Chapter 3. In Chapter 2, the group with cTnI level above the cut-off 26.2 pg/mL 
and the group with BNP level above the cut-off 40 pg/mL showed significantly high 
FRS and CTR. In Chapter 3, the group with BNP level less than 4 pg/mL showed 
inversed association with cTnI, indicating a potential for cTnI elevation. 
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Fig. 2: Schematic Diagram of the Concept of Risk Stage in the Case of 
Cardiovascular Diseases 
Schematic diagram to show differentiating stages of risks; a risk as a causing factor and 
a risk as a resulting factor. The former risk includes smoking, hypertension, 
dyslipidemia, diabetes and chronic kidney disease. The latter risk includes myocardial 
hypertrophy where BNP is the indicator and myocardial injury where cTnI is the 
indicator. 
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Fig. 3: Schematic Diagram of the Concept of Risk Stage in the Case of 
Malignant Tumor Development 
Schematic diagram to show differentiating stages of risks; a risk as a causing factor and 
a risk as a resulting factor. The former risk includes obesity, western-style diet, toxic 
chemicals and weakening immunity. The latter risk includes constitutive growth signal, 
anti-apoptosis, unresponsiveness to cell-to-cell contact inhibition, immune-inactivation, 
secretion of growth factors and enhanced ability of cell adhesion and infiltration. 
Human epididymis protein 4, or HE4, is deemed as the candidate biomarker as the 
indicator for tumor growth factor and enhanced ability of cell adhesion and infiltration. 
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